| 000 | 01415 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250518003106.0 | ||
| 264 | 0 | _c20190121 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-018-4891-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKim, Min Kyoung | |
| 245 | 0 | 0 |
_aRisk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. _h[electronic resource] |
| 260 |
_bBMC cancer _cOct 2018 |
||
| 300 |
_a988 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A Inducers _xtherapeutic use |
| 650 | 0 | 4 |
_aErlotinib Hydrochloride _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 |
_aLiver Neoplasms _xsecondary |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aYee, Jeong | |
| 700 | 1 | _aCho, Yoon Sook | |
| 700 | 1 | _aJang, Hong Won | |
| 700 | 1 | _aHan, Ji Min | |
| 700 | 1 | _aGwak, Hye Sun | |
| 773 | 0 |
_tBMC cancer _gvol. 18 _gno. 1 _gp. 988 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-018-4891-7 _zAvailable from publisher's website |
| 999 |
_c28944712 _d28944712 |
||